Linked Life Data

15813427

Source:http://linkedlifedata.com/resource/pubmed/id/15813427

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2005-4-7
pubmed:abstractText
Gene-expression profiles are a promising development in determining the prognosis of patients with primary breast cancer. They accurately assess the risk on distant recurrence of disease and show if the patient might benefit from adjuvant therapy after surgery thus minimising the risk of distant metastases. Three clinically relevant profiles on prognosis have now been published, two of which come from the Netherlands, and whose results are an improvement on those using traditional clinical parameters i.e. the St. Gallen and the National Institutes of Health criteria. These gene-expression profiles mean that 25-40% of patients need no longer undergo adjuvant systemic therapy (chemotherapy and/or endocrine therapy). Although the risk-stratifying power of these profiles has been established, their power in predicting the response of the patients to adjuvant systemic therapy still awaits scientific proof.
pubmed:commentsCorrections
pubmed:language
dut
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0028-2162
pubmed:author
pubmed:issnType
Print
pubmed:day
19
pubmed:volume
149
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
618-22
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
[The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer].
pubmed:affiliation
Erasmus Medisch Centrum, Daniel den Hoed Kliniek, afd. Interne Oncologie, Groene Hilledijk 301, 3075 EA Rotterdam. j.g.m.klijn@erasmusmc.nl
pubmed:publicationType
Journal Article, Comment, English Abstract